EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

Current Oncology Reports

Volumn 10, Issue 2, 2008, Pages 176-184

  Mehra, Ranee ^b   Cohen, Roger B ^b   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM COMPLEX; TRASTUZUMAB; VANDETANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BACTEREMIA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPOMAGNESEMIA; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PNEUMONIA; RASH; RECEPTOR BINDING; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SKIN INFECTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TINNITUS; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 40849136245     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0027-6     Document Type: Review

References (70)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Herrero R, Castellsague X, Pawlita M, et al.: Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003, 95:1772-1783.
3. Forastiere AA, Maor M, Weber RS, et al.: Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx - induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy [ASCO abstract]. J Clin Oncol 2006, 24(18S):5517.
4. Posner MR, Hershock D, Le Lann L et al.: TAX 324: a phase III trial at TPF vs. PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCHN. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006; Atlanta, GA.
5. Burtness B, Goldwasser MA, Flood W, et al.: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
6. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
7. Cohen S, Carpenter G, King L, Jr: Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980, 255:4834-4842.
8. Masui H, Kawamoto T, Sato JD, et al.: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44:1002-1007.
9. Prigent SA, Lemoine NR: The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992, 4:1-24.
10. O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 2002, 38:627-640.
11. Hambek M, Baghi M, Baumaun H, et al.: Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN). Anticancer Res 2005, 25:1871-1875.
12. Psyrri A, Weinberger P, Yu Z, et al.: Correlates and determinants of nuclear epidermal growth factor receptor (EGFR) content in an oropharyngeal cancer tissue microarray [ASCO abstract]. J Clin Oncol 2007, 25(18S):6022.
13. Schlessinger J Lemmon MA: Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 2006, 127:45-48.
14. Haura EB, Zheng Z, Song L, et al.: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005, 11:8288-8294.
15. Lo HW, Hsu SC, Ali-Seyed M, et al.: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589.
16. Rubin Grandis J, Melhem MF, Gooding WE, et al.: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
17. Dassonville O, Formento JL, Francoual M, et al.: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-1878.
18. Ang KK, Berkey BA, Tu X, et al.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
19. Sheridan MT, O'Dwyer T, Seymour CB, et al.: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997, 5:180-186.
20. Balaban N, Moni J, Shannon M, et al.: The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996, 1314:147-156.
21. Milas L, Mason K, Hunter N, et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708.
22. Harari PM, Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001, 49:427-433.
23. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935-1940.
24. Kiyota A, Shintani S, Mihara M, et al.: Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 2002, 63:92-98.
25. Friedmann B, Caplin M, Hartley JA, et al.: Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004, 10:6476-6486.
26. Yacoub A, McKinstry R, Hinman D, et al.: Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003, 159:439-452.
27. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000, 6:2166-2174.
28. Friedmann BJ, Caplin M, Savic B, et al.: Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006, 5:209-218.
29. Kies MS, Ghebremichael MS, Katz TL, et al.: EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2007 (18S):6024
30. Chung CH, Ely K, McGavran L, et al.: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-4176.
31. Li S, Schmitz KR, Jeffrey PD, et al.: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
32. Sigismund S, Woelk T, Pun C, et al.: Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A 2005, 102:2760-2765.
33. Cartron G, Dacheux L, Salles G, et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
34. Johns TG, Adams TE, Cochran JR, et al.: Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004, 279:30375-30384.
35. Trigo J, Hitt R, Koralewski P, et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [ASCO abstract]. J Clin Oncol 2004, 22(14S):5502.
36. Robert F, Ezekiel MP, Spencer SA, et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19:3234-3243.
37. Pfister DG, Su YB, Kraus DH, et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006, 24:1072-1078.
38. Suntharalingam M, Taylor R, Wolf J, et al.: Initial report of phase II trial of weekly cetuximab, CBDCA, paclitaxel and daily RT in patients with locally advanced SCCHN. Presented at the Multidisciplinary Head and Neck Cancer Symposium. January 18-20, 2007; Rancho Mirage, CA.
39. Savvides P, Argarwala S, Greskovich J, et al.: Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2006, 24(18S):5545.
40. Herchenhorn D, Dias FL, Ferreira CG: Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2006, 24(18S):5575.
41. Herchenhorn D, Dias FL, Pineda RM, et al.: Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2007, 25(18S):6033.
42. Doss HH, Greco FA, Meluch AA, et al.: Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network [ASCO abstract]. J Clin Oncol 2006, 24(18S):5543
43. Cohen EE, Haraf DJ, Stenson KM, et al.: Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC): a phase II trial [ASCO abstract]. J Clin Oncol 2005, 23(16S):5506.
44. Ahmed SM, Cohen EE, Haraf DJ, et al.: Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) [ASCO abstract]. J Clin Oncol 2007, 25(18S):6028.
45. Argiris A, Karamouzis MV, Heron DE, et al.: Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC) [ASCO abstract]. J Clin Oncol 2007, 25(18S):6051.
46. Wanebo HJ, Ghebremichael M, Burtness B, et al.: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, pactitaxel, carboplatin, and radiation for stage III/ IV operable squamous cancer of the head and neck (ECOG, E2303) [ASCO abstract]. J Clin Oncol 2007, 25(18S):6015
47. Numico G, Colantonio I, Heouaine A, et al.: Compassionate treatment (CTr) with re-irradiation, carboplatin (Cb) and cetuximab (C) in very advanced head and neck cancer (HNC) [ASCO abstract]. J Clin Oncol 2006, 24(18S):13153.
48. Crombet T, Osorio M, Cruz T, et al.: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22 1646-1654.
49. Wirth LJ, Posner M, Tishler RB, et al.: Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results [ASCO abstract]. J Clin Oncol 2007, 25(18S):6083.
50. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
51. Cohen EE, Lingen MW, Martin LE, et al.: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005, 11:8105-8108.
52. Burris HA, III, Hurwitz HI, Dees EC, et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pre-treated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
53. Harrington K, Bourhis J, Nutting CM, et al.: A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2006, 24(18S):5553.
54. Baselga J, Trigo JM, Bourhis J, et al.: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:5568-5577.
55. Herbst RS, Arquette M, Shin DM, et al.: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:5578-5587.
56. Vermorken JB, Trigo J, Hitt R, et al.: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25:2171-2177.
57. Soulieres D, Senzer NN, Vokes EE, et al.: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22:77-85.
58. Cohen EE, Kane MA, List MA, et al.: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005, 11:8418-8424.
59. Cohen EE, Rosen F, Stadler WM, et al.: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003, 21:1980-1987.
60. Abidoye OO, Cohen EE, Wong SJ, et al.: A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [ASCO abstract]. J Clin Oncol 2006, 24(18S):5568.
61. Baselga J, Pfister D, Cooper, MR, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904-914.
62. Bourhis J, Rivera F, Mesia R, et al.: Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2866-2872.
63. Siu LL, Soulieres D, Chen EX, et al.: Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007, 25:2178-2183.
64. Hitt R, Irigoyen A, Nuñez J, et al.: Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) [ASCO abstract]. J Clin Oncol 2007, 25(18S):6012.
65. Kim ES, Kies MS, Glisson BS, et al.: Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/ metastatic head and neck cancer [ASCO abstract]. J Clin Oncol 2007, 25(18S):6013.
66. Vermorken J, Mesia R, Vega V, et al.: Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (Extreme) study. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Abstract 6091.
67. Yano S, Kondo K, Yamaguchi M, et al.: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003, 23:3639-3650.
68. Harari PM, Durland WE, Chinnaiyan P, et al.: Impact of the EGFR inhibitor C225 on wound healing in advanced head & neck cancer patients undergoing neck dissection [abstract]. Proc Am Soc Clin Oncol 2003, 22:abstract 881.
69. Bonner JA, Harari P, Giratt J, et al.: Duration of mucositis and dysphagia following radiotherapy (+ cetuximab) for locoregionally advanced head and neck cancer. Presented at the Multidisciplinary Head and Neck Cancer Symposium. January 18-20, 2007; Rancho Mirage, CA.
70. Erbitux [package insert]. ImClone Systems Inc. and Bristol-Myers Squibb: New York, NY and Princeton, NJ; 2007.